Varaz Bozoghlanian, MD
Allergy & Immunology · Tarzana, CANPI 1174751382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,611 of the $4,805 with a category attached, or 75.2%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,269 and has fallen 73.4% since, to $603 in 2025.
Across 182 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$585
- AstraZeneca$424
- Sanofi$405
- Novartis$306
- GSK$286
- plus $2K from 21 others
Across 4 payments — averaging $1197.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Consulting fees$1,12523%
- Food & beverage$3,61175%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Regeneron Healthcare Solutions, Inc. | 29 | $585 |
| AstraZeneca | 23 | $424 |
| Sanofi | 18 | $405 |
| Novartis | 15 | $306 |
| GSK | 18 | $286 |
| Shire North American Group Inc | 9 | $184 |
| Pharming Healthcare, Inc. | 2 | $164 |
| Alk-abello, Inc | 9 | $138 |
| CSL Behring | 7 | $132 |
| Genentech USA, Inc. | 6 | $129 |
| AbbVie | 5 | $125 |
| Amgen(2 entities) | 4 | $108 |
| Sanofi-aventis U.S. LLC | 4 | $108 |
| Pfizer | 5 | $107 |
| Boehringer Ingelheim | 5 | $95 |
| Sunovion Pharmaceuticals Inc. | 4 | $66 |
| Optinose US, Inc. | 3 | $63 |
| Octapharma USA, Inc. | 3 | $52 |
| Kaleo, Inc. | 2 | $40 |
| Grifols USA, LLC | 2 | $37 |
| Bio Products Laboratory USA, Inc. | 2 | $30 |
| Viatris Specialty LLC | 2 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$131
How this compares
$4,805 in reported general payments places this provider in the 60th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 73 | $269,775 |
| Dupixent SyringeDupilumab | 45 | $164,304 |
| XolairOmalizumab | 21 | $69,869 |
| RinvoqUpadacitinib | 11 | $68,107 |
| FasenraBenralizumab | 11 | $61,850 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $38,205 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $22,361 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $21,507 |
| Arnuity ElliptaFluticasone Furoate | 53 | $14,080 |
| XhanceFluticasone Propionate | 11 | $11,266 |
| DuleraMometasone/Formoterol | 14 | $7,422 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,904 |
| Ipratropium Bromide | 94 | $2,835 |
| Epinephrine | 17 | $2,778 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $424 | $87,26050 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $286 | $74,646142 claims |
| AbbVieRinvoq | $125 | $68,10711 claims |
| Optinose US, Inc.Xhance | $63 | $11,26611 claims |
| PfizerPaxlovid | $107 | $1,42912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Tarzana
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
- Myron LiebhaberSanta Barbara$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.